Paper2803953
Cisplatin/carboplatin cross-resistance in ovarian cancer.
Gore ME and 5 others. Br J Cancer, 1989. Cited by 106 papers, by iCite.
Cite this record
ConductScience Library. Cisplatin/carboplatin cross-resistance in ovarian cancer. Papers, record 2803953. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2803953
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma | Major topic |
| Cisplatin | Major topic |
| Ovarian Neoplasms | Major topic |
| Adult | |
| Drug Resistance | |
| Female | |
| Humans |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4038381 | Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. | Cancer Res | 1985 | https://conductscience.org/library/papers/4038381 | PubMed |
| 2 | 6315233 | Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. | Cancer Treat Rep | 1983 | https://conductscience.org/library/papers/6315233 | PubMed |
| 3 | 3910224 | Ovarian trials at the Royal Marsden. | Cancer Treat Rev | 1985 | https://conductscience.org/library/papers/3910224 | PubMed |
| 4 | 3512077 | Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. | Cancer Res | 1986 | https://conductscience.org/library/papers/3512077 | PubMed |
| 5 | 3517243 | A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. | J Clin Oncol | 1986 | https://conductscience.org/library/papers/3517243 | PubMed |
| 6 | 3543243 | High-dose carboplatin in refractory ovarian cancer patients. | J Clin Oncol | 1987 | https://conductscience.org/library/papers/3543243 | PubMed |
| 7 | 2898306 | Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. | Carcinogenesis | 1988 | https://conductscience.org/library/papers/2898306 | PubMed |
| 8 | 1000519 | Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. | Cancer Treat Rep | 1976 | https://conductscience.org/library/papers/1000519 | PubMed |
| 9 | 404216 | Second trial drugs in ovarian cancer. | Gynecol Oncol | 1977 | https://conductscience.org/library/papers/404216 | PubMed |
| 10 | 350392 | Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/350392 | PubMed |
| 11 | 498148 | Rationale for development of platinum analogs. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/498148 | PubMed |
| 12 | 387224 | cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/387224 | PubMed |
| 13 | 7197985 | Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. | Br J Obstet Gynaecol | 1981 | https://conductscience.org/library/papers/7197985 | PubMed |
| 14 | 6761010 | Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6761010 | PubMed |
| 15 | 2993535 | High-dose cisplatin in hypertonic saline in refractory ovarian cancer. | J Clin Oncol | 1985 | https://conductscience.org/library/papers/2993535 | PubMed |
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39356625 | Resistance Management for Cancer: Lessons from Farmers. | Cancer Res | 2024 | https://conductscience.org/library/papers/39356625 | PubMed |
| 36499737 | Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36499737 | PubMed |
| 33076245 | Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33076245 | PubMed |
| 32194363 | CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro. | EXCLI J | 2020 | https://conductscience.org/library/papers/32194363 | PubMed |
| 32039434 | Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion. | Biochem J | 2020 | https://conductscience.org/library/papers/32039434 | PubMed |
| 32022814 | Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer. | Dalton Trans | 2020 | https://conductscience.org/library/papers/32022814 | PubMed |
| 31174889 | A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. | Gynecol Oncol | 2019 | https://conductscience.org/library/papers/31174889 | PubMed |
| 30709915 | Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase η. | Biochem J | 2019 | https://conductscience.org/library/papers/30709915 | PubMed |
| 29069808 | Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. | Oncotarget | 2017 | https://conductscience.org/library/papers/29069808 | PubMed |
| 25444929 | Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells. | Cancer Lett | 2015 | https://conductscience.org/library/papers/25444929 | PubMed |
| 24874729 | Systems biology of cisplatin resistance: past, present and future. | Cell Death Dis | 2014 | https://conductscience.org/library/papers/24874729 | PubMed |
| 24155778 | UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance. | J Cancer | 2013 | https://conductscience.org/library/papers/24155778 | PubMed |
| 23349823 | Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. | PLoS One | 2013 | https://conductscience.org/library/papers/23349823 | PubMed |
| 19688066 | Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. | Cancer Res Treat | 2009 | https://conductscience.org/library/papers/19688066 | PubMed |
| 14576837 | Cisplatin: mode of cytotoxic action and molecular basis of resistance. | Oncogene | 2003 | https://conductscience.org/library/papers/14576837 | PubMed |
| 11085200 | Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. | Drugs | 2000 | https://conductscience.org/library/papers/11085200 | PubMed |
| 9649119 | Anti-proliferative activity and mechanism of action of titanocene dichloride. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9649119 | PubMed |
| 9092638 | Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides. | Nucleic Acids Res | 1997 | https://conductscience.org/library/papers/9092638 | PubMed |
| 8980393 | The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8980393 | PubMed |
| 8573296 | Comparative adverse effect profiles of platinum drugs. | Drug Saf | 1995 | https://conductscience.org/library/papers/8573296 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2803953
GET https://conductscience.org/api/papers/v1/2803953/cited_by?page=2